Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sevelamer carbonate - Sanofi Genzyme

Drug Profile

Sevelamer carbonate - Sanofi Genzyme

Alternative Names: GZ 419831; Renvela

Latest Information Update: 04 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Polyamines
  • Mechanism of Action Chelating agents; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia

Most Recent Events

  • 21 Dec 2016 Sanofi plans the phase III RECOVER trial for Hyperphosphataemia in China (PO, Tablet) (NCT03001011)
  • 01 Jun 2015 Genzyme completes a phase II trial in Hyperphosphataemia (In adolescents, In children, In infants) in Poland, Lithuania, Germany, France and USA (NCT01574326)
  • 31 Mar 2014 First generic equivalent available in USA for hyperphosphataemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top